Publicaciones en colaboración con investigadores/as de Complejo Asistencial Universitario de Burgos (12)

2023

  1. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

    Cancers, Vol. 15, Núm. 5

  2. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

    eClinicalMedicine, Vol. 65

2022

  1. ABCL-297 Hemophagocytic Lymphohistiocytosis Singularity: A Multicenter Retrospective Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S369-S370

  2. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

2020

  1. Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder

    Leukemia and Lymphoma

  2. Reply to Brown et al: ‘Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis’

    Leukemia and Lymphoma

2018

  1. A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group

    American Journal of Hematology, Vol. 93, Núm. 7, pp. 867-873

  2. Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study

    Annals of Hematology, Vol. 97, Núm. 3, pp. 475-484

2016

  1. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center

    Thrombosis Research, Vol. 142, pp. 52-56

2015

  1. Estudio de incidencia de las neoplasias hematopoyéticas en Castilla y León

    Medicina Clinica, Vol. 144, Núm. 11, pp. 491-500

  2. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant

    British Journal of Haematology, Vol. 169, Núm. 5, pp. 719-725

2013

  1. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728